Birch pollen allergoid - Allergopharma Joachim Ganzer KG
Latest Information Update: 05 Jul 2016
At a glance
- Originator Allergopharma
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Seasonal allergic rhinitis
Most Recent Events
- 20 Jun 2016 Allergopharma initiates a phase II trial for Seasonal allergic rhinitis in Germany (EudraCT2015-005400-28)